AMNEAL PHARMACEUTICALS, INC. AMRX
19.77
(0.04)
(0.20%)
as of 25 Sep
- Market cap
- $6.3B
- P/E
- 39.5×
Follow AMRX
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
500.50 | 54.78 | 31.87 | 34.62 |
P/S ratio |
1.07 | 1.31 | 1.29 | 1.77 | |
P/FCF ratio |
13.22 | 17.34 | 20.71 | 0.00 | |
P/Operating CF |
26.55 | 30.30 | (146.89) | (260.09) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 167.31 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.87 | 2.06 | 2.09 | 2.59 | |
EV/EBITDA |
8.79 | 9.70 | 9.60 | 12.12 | |
EV/Operating CF |
16.73 | 18.26 | 20.77 | 40.14 | |
EV/FCF |
23.05 | 27.27 | 33.50 | (695.25) | |
Quick Ratio |
1.30 | 1.37 | 1.45 | 1.31 | |
Current Ratio |
2.13 | 2.17 | 2.47 | 2.20 | |
Net Debt/EBITDA |
18.06 | 13.71 | 12.84 | 13.95 | |
Debt/Assets |
71.49% | 69.92% | 74.19% | 70.71% | |
Debt/Equity |
(23.41) | (36.06) | (57.14) | 80.86 | |
Asset Turnover |
0.83 | 0.84 | 0.88 | 0.87 | |
Operating CF/Net income |
50.00 | 3.72 | (0.43) | (0.37) | |
Capex/Depreciation |
(0.38) | (0.86) | (0.46) | (2.37) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.08% | 4.28% | 5.31% | 4.90% | |
Selling, General and Administrative Expense of Revenue |
17.57% | 17.99% | 19.22% | 18.68% | |
Intangible Assets out of Total Assets |
0.33 | 0.32 | 0.32 | 0.31 | |
Share Based Compensation of Revenue |
1.05% | 1.01% | 1.22% | 1.31% | |
Graham Net Nets |
(0.60) | (0.47) | (0.46) | (0.33) | |
Graham Number |
0.00 | 0.00 | 0.00 | 1.08 | |
Earnings Yield |
0.20% | 1.83% | 3.14% | 2.89% | |
Free Cash Flow Yield |
7.56% | 5.77% | 4.83% | (0.21%) | |
Revenue per Share |
2.50 | 2.60 | 2.29 | 2.49 | |
Operating CF per Share |
0.38 | 0.42 | (0.08) | (0.07) | |
Capex per Share |
(0.07) | (0.15) | (0.07) | (0.38) | |
Free Cash Flow per Share |
0.31 | 0.27 | (0.15) | (0.45) | |
Cash per Share |
0.75 | 0.99 | 0.64 | 0.43 | |
Shareholders Equity per Share |
(0.35) | (0.23) | (0.15) | 0.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.35) | (0.23) | (0.15) | 0.10 | |
Free Cash Flow |
95.99 | 84.86 | (48.45) | (143.99) | |
Working Capital |
976.37 | 1,029.55 | 1,069.86 | 1,063.84 | |
Capital Expenditures |
(22.46) | (45.45) | (21.71) | (122.74) | |
Net Current Asset Value |
(1,871.35) | (1,838.43) | (1,788.28) | (1,796.29) | |
EV/EBIT |
15.32 | 15.76 | 14.59 | 17.76 | |
Capex to Sales |
0.03 | 0.06 | 0.03 | 0.15 | |
Net Profit Margin |
0.30% | 4.31% | 8.62% | 7.24% | |
Price to Operating Income |
8.79 | 10.02 | 9.02 | 12.17 | |
| Other line items | |||||
Average Receivables |
821.56 | 835.91 | 803.05 | 915.01 | |
Average Payables |
701.46 | 748.38 | 645.77 | 694.01 | |
Average Inventory |
605.43 | 609.38 | 621.53 | 643.46 | |
Average Assets |
3,530.43 | 3,589.86 | 3,452.73 | 3,599.57 | |
Average Common Equity |
(101.76) | (90.42) | (88.98) | (39.75) |
Columns are period end dates